Analyst Alan Carr works at NEEDHAM and is focused on the Healthcare sector with 124 price targets and ratings documented since 2013 spanning on 15 stocks. Analyst's average stock valuation to be materialised ratio is 58.27% with an average time for price targets to be met of 167.8 days.
Most recent stock forecast was given on CRSP, CRISPR Therapeutics AG at 13-May-2022.
Alan Carr best performing recommendations are on ALNY (ALNYLAM PHARMACEUTICALS, INC).
The best stock recommendation documented was for ALNY (ALNYLAM PHARMACEUTICALS, INC) at 9/19/2017. The price target of $85 was fulfilled within 1 day with a profit of $9.96 (13.27%) receiving and performance score of 132.73.
Average potential price target upside